November 2025
Diatech Pharmacogenetics Market Share Analysis for November 2025
DPYD Genotyping in Fluoropyrimidine Therapy: Reducing Toxicity, Improving Outcome
Fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, and tegafur are widely used in oncology, treating over 3.5 million patients annually—with 600,000 in Europe alone. Despite their effectiveness, these drugs carry a significant risk of toxicity: 10–40% of patients develop severe side effects (Grade 3–4) requiring hospitalisation and occasionally
Diatech Pharmacogenetics (including company regionals)
See more website traffic and engagement information- diatechpharmacogenetics.com
Diatech Pharmacogenetics Revenue up to November 2025 is 2M - 5M
revenue generated by Diatech Pharmacogenetics top domains
Diatech Pharmacogenetics top domains revenue over 3 years
Revenue for Diatech Pharmacogenetics top domains
Total visits to Diatech Pharmacogenetics's top domains
Understand Diatech Pharmacogenetics market share and potential market reach.
Total visits last 3 months
Subsidiaries Breakdown
Avg. visit duration in Diatech Pharmacogenetics's top domains
Analyze Diatech Pharmacogenetics engagement metrics.
Average visit duration last 3 months
Subsidiaries Breakdown
Avg. pageviews on Diatech Pharmacogenetics's top domains
See how Diatech Pharmacogenetics keep users engaged, nurture their interest, and encourage them to take the next step.
Average page views last 3 months
Subsidiaries Breakdown
